Trials & Filings
Related Searches:
Filter by:
226 - 240 of 604 results
July 27, 2009
Tranzyme Pharma’s oral gastrointestinal (GI) prokinetic drug candidate TZP-102, for the treatment of gastroparesis in diabetic patients, was granted Fast Track designation from the FDA.
Read More »
July 21, 2009
Spectrum Pharmaceuticals received Fast Track designation from the FDA for apaziquone in bladder cancer.
Read More »
July 20, 2009
Orexigen Therapeutics reported that all three Phase III trials of Contrave met their co-primary endpoints for the treatment of obesity.
Read More »
July 14, 2009
Wyeth received approval from the Chilean Ministry of Health, MINSAL (Ministerio de Salud), for Prevenar 13 Valent.
Read More »
July 13, 2009
The FDA has approved the NDA by Daiichi Sankyo and Eli Lilly and Co. for Effient (prasugrel) tablets
Read More »
July 8, 2009
Biogen Idec's PEGylated interferon beta-1a (BIIB017) for relapsing multiple sclerosis (RMS) was granted Fast Track designation by the FDA.
Read More »
July 6, 2009
The European Commission has granted marketing authorization for Novo Nordisk's Victoza for the treatment of type 2 diabetes in adults
Read More »
July 2, 2009
The FDA has approved Sanofi-Aventis's Multaq (dronedarone) 400 mg tablets for patients with atrial fibrillation (AF) or atrial flutter (AFL).
Read More »
July 1, 2009
Pfizer is discontinuing the SUN 1122 Phase III trial evaluating Sutent plus FOLFIRI (irinotecan plus infusional 5-fluorouracil and leucovorin) versus FOLFIRI alone for the first-line treatment of metastatic colorectal cancer (CRC).
Read More »
June 25, 2009
Teva, Active to begin second Phase III trial of Avonex competitor.
Read More »
June 25, 2009
Sutent doubled median progression-free survival in patients with pancreatic neuroendocrine tumors
Read More »
June 22, 2009
Biogen Idec has enrolled the first patient in a Phase III trial of PEGylated interferon beta-1a.
Read More »
June 18, 2009
Novartis received approval from the FDA for Ilaris (canakinumab) for the treatment of children and adults with cryopyrin-associated periodic syndrome (CAPS), which includes a number of rare but life-long auto-inflammatory disorders with debilitating sympt
Read More »
June 5, 2009
Merck's preliminary results for the Phase III study of rolofylline (MK-7418), an investigational medicine for the treatment of acute heart failure, shows that rolofylline did not meet the primary or secondary efficacy endpoints.
Read More »
May 27, 2009
Bristol-Myers Squibb received full approval from the FDA for Sprycel (dasatinib) for the treatment of adults in all phases of chronic myeloid leukemia (CML) (chronic, accelerated, or myeloid or lymphoid blast phase) with resistance or intolerance to prior
Read More »
226 - 240 of 604 results
